Home / Companies / Knight Therapeutics
Company family
Knight Therapeutics: medicine shortages
As of 2 Nov 2026, 10 Knight Therapeutics products have a reported shortage across 1 countries, covering 8 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Dantrolene | 2 | 20 Apr 2026 | Manufacturing problem | 3/16 | |
| Doxepin | 2 | 15 Sep 2026 | Other | 2/16 | |
| Glyceryl Trinitrate | 1 | 7 Oct 2026 | Other | 6/16 | |
| Methadone | 1 | 16 Jul 2026 | Distribution or logistics | 4/16 | |
| Neratinib | 1 | 14 Jul 2026 | Distribution or logistics | 1/16 | |
| Pizotifen | 1 | 2 Oct 2023 | Other | 1/16 | |
| Tapentadol | 1 | 5 Oct 2026 | Distribution or logistics | 3/16 | |
| Tenapanor | 1 | 31 Mar 2026 | Other | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.